NRXP NRX Pharmaceuticals, Inc.
Listings ·
Nasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026.
NRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares.
The $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.
NRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date.
NRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures.
NRx Pharmaceuticals is a clinical-stage bio-pharmaceutical company developing treatments for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder and schizophrenia. Its drug candidates enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor. The three lead candidates are NRX-100, a preservative-free intravenous ketamine formulation, KETAFREE, a generic preservative-free ketamine formulation, and NRX-101, an oral fixed dose combination of D-cycloserine and lurasidone. The company is the founder and majority owner of HOPE Therapeutics, which offers interventional psychiatry care for treatment-resistant depression and PTSD using ketamine, transcranial magnetic stimulation, digital therapeutics and hyperbaric therapy. The company filed an Abbreviated New Drug Application for KETAFREE with priority review requested, and it expects to file a New Drug Application for NRX-100 in Q2 2026.
| Product or program | What it is | Stage |
|---|---|---|
| NRX-100 | Preservative-free intravenous ketamine formulation for suicidal depression | NDA expected to be filed in Q2 2026; Fast Track Designation awarded |
| KETAFREE | Generic preservative-free ketamine formulation for intravenous use | ANDA filed; commercial sales planned with FDA approval in Q3 2026 |
| NRX-101 | Oral fixed dose combination of D-cycloserine and lurasidone | NDA initiated; Breakthrough Therapy Designation previously awarded |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.2 million | $0 |
| Research and development | $3.8 million | $6.2 million |
| Net income (loss) | -$28.6 million | -$25.1 million |
| Cash from operations | -$14.1 million | -$10.6 million |
| Cash and equivalents | $7.8 million | $1.4 million |
Our latest story on this, dated Sep 8, 2025: "NRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 16, 2026: "NRX Pharmaceuticals gets Nasdaq notice for missing annual meeting deadline". The story links the filing or release it is based on. Read the story.
NRX Pharmaceuticals, Inc. trades under the ticker NRXP on NASDAQ.
NRX Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:B1Q; LSX:A4091K.
The SEC Central Index Key (CIK) for NRX Pharmaceuticals, Inc. is 1719406. Its filings are on SEC EDGAR.
43,295,767 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records NRX Pharmaceuticals, Inc. under United States.
Our directory classifies NRX Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for NRX Pharmaceuticals, Inc. is US6294442099.
aibio.space lists NRX Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
NRx Pharmaceuticals is a clinical-stage bio-pharmaceutical company developing treatments for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder and schizophrenia. Its drug candidates enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor.
NRX-100: Preservative-free intravenous ketamine formulation for suicidal depression Stage: NDA expected to be filed in Q2 2026; Fast Track Designation awarded.
KETAFREE: Generic preservative-free ketamine formulation for intravenous use Stage: ANDA filed; commercial sales planned with FDA approval in Q3 2026.
$1.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio